Pillar

About us

Founded in 2023, Belnord is an independent alternatives investment firm established by a team with deep experience across leading global investment institutions.

We specialise in GP solutions, primarily across secondaries and co-investments, forging strategic partnerships with European mid-market private equity managers. With a hands-on investment approach and a strong network, we unlock high-quality deal flow. As committed investors, we invest significant capital into our own funds, ensuring alignment with our partners.

Headquartered in Stockholm, Sweden, Belnord is shaping the next generation of European private markets investing.

Investment Strategy

GP-led secondaries

Single-asset continuation vehicles

Direct investments

Co-investments

Other liquidity solutions

E.g. single-line fund transfers

Selected portfolio investments

Medix Biochemica

Website
Global leader in critical components for diagnostic tests

Sector:

Healthcare

HQ:

Finland

Founded in 1985 with over 250 employees, Medix Biochemica is a leading independent supplier of critical biological raw material products to the in vitro diagnostics (IVD) industry worldwide. The company develops, produces, and supplies high-quality antibodies, antigens, and other critical IVD raw material products to IVD test manufacturers around the world, enabling the delivery of accurate IVD tests to billions of patients worldwide.

The company’s expertise covers various market segments including immunoassay, clinical chemistry and molecular diagnostics. Medix Biochemica serves its global customers through local teams in North America, Europe, and China.

Immedica

Website
Pharmaceutical company specialising in the commercialisation of medicines for rare diseases and specialty care

Sector:

Healthcare

HQ:

Sweden

Founded in 2018 with c. 120 employees, Immedica is engaged in the launch, commercialisation and distribution of orphan and niche specialty pharmaceuticals across Europe and the Middle East. Currently, Immedica distributes a portfolio of c. 25 drugs, spanning proprietary, in-licensed and partnered products with a focus on genetic and metabolic diseases, oncology, and ophthalmology.

Immedica is quickly scaling across Europe and recently entered the USA with a vision to become the leading player in launching niche specialty pharmaceuticals targeting diseases with high unmet medical needs.

Yaveon

Website
Independent software vendor, value added reseller and system integrator specialised in Microsoft Dynamics Business Central

Sector:

Software

HQ:

Germany

Founded in 2008 with more than 200 employees, Yaveon is a leading ERP software vendor and system integrator specialising in the Microsoft Dynamics ERP platform. The company serves small and medium companies operating in the process manufacturing industry, including the highly regulated life sciences industry. In addition to in-depth industry know-how, Yaveon offers a proprietary suite of industry extensions.